A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Donskov, Frede; Jensen, Niels Viggo; Smidt-Hansen, Torben; Brøndum, Line; Geertsen, Poul F.

doi:10.1080/0284186x.2018.1433324

Cited by 17 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two included studies, encompassing 198 patients, reported on the prevalence of VTE in renal cancer patients [ 48 , 105 ]. However, a meta-analysis could not be performed due to insufficient number of studies.…”

Section: Resultsmentioning

confidence: 99%

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Sun

Bhaskar

2022

Diagnostics

View full text Add to dashboard Cite

Objective: Venous thromboembolism (VTE) is a life-threatening complication that may exacerbate cancer prognosis. Whilst some studies indicate an increased risk of VTE in cancer patients undergoing chemotherapy, the prevalence estimates on the pooled prevalence of VTE in cancer patients undergoing chemotherapy are not known. This study aims to calculate the pooled prevalence of VTE in chemotherapy-treated cancer patients. Methods: Studies on VTE occurrence in cancer patients undergoing chemotherapy were retrieved after database search. The terms used included “cancer”, “chemotherapy”, and “venous thromboembolism”. A random-effects meta-analysis was conducted to obtain a pooled estimate of VTE prevalence in cancer patients undergoing chemotherapy. Results: A total of 102 eligible studies involving 30, 671 patients (1773 with VTE, 28, 898 without) were included in the meta-analysis. The pooled estimate of VTE prevalence was found to be 6%, ranging from 6 to 7% (ES 6%; 95% CI 6–7%; z = 18.53; p < 0.001). Conclusions: The estimated pooled prevalence rate of VTEs was 6% in cancer patients undergoing CRT, which was higher than the overall crude prevalence rate (5.78%). Comprehensive cancer care should consider stratified VTE risk assessment based on cancer phenotype, given that certain phenotypes of cancer such as bladder, gastric and ovarian posing particularly high risks of VTE.

show abstract

Section: Resultsmentioning

confidence: 99%

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Sun

Bhaskar

2022

Diagnostics

View full text Add to dashboard Cite

show abstract

“…In contrast, MVD did not show prognostic potential, and moreover, MVD did not correlate to baseline patient characteristics, to DCE-CT parameters BV or BF, or to HU. Despite only 25 patients had evaluable scans and tumours, this study represents the largest cohort of patients with metastatic renal cell carcinoma examined to date with an integrated prospectively obtained functional imaging CT and corresponding biopsy design [ 8 ]; all analyses were preplanned per protocol.…”

Section: Discussionmentioning

confidence: 99%

“…The clinical results from DaRenCa-1 [ 8 ], the prognostic impact on survival outcome of baseline DCE-CT identified BV [ 15 ], and the association between DCE-CT parameters and early treatment response [ 16 – 18 ] in this patient group have previously been published.…”

Section: Methodsmentioning

confidence: 99%

“…or J.M.) defined either a primary tumour or metastasis as a target lesion at baseline, suitable for core biopsy and functional imaging using CT [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

“…The disease can also be treated with immunotherapy: interferon-alpha (INF-α2b, IntronA: Merck & Co., Whitehouse Station, NJ) and interleukin-2 (aldesleukin, Proleukin: Novartis Vaccines and Diagnostics, East Hanover, NJ) were first shown to be effective [ 6 ] followed by the checkpoint inhibitors nivolumab (Opdivo: Bristol Myers Squibb, New York, NY) and ipilimumab (Yervoy: Bristol Myers Squibb, New York, NY) [ 7 ]. Recently, immunotherapy combined with VEGF inhibitors has shown promising activity [ 8 – 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results At baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration NCT01274273

show abstract

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Aldin

Besiroglu

Adams

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Abstract: The addition of BEV to IL-2/IFN did not add efficacy in mRCC. (ClinicalTrials.gov, NCT01274273.).

Cited by 17 publications

References 33 publications

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Contact Info

Product

Resources

About